Entresto, also known as sacubitril/valsartan, is a medication used to treat heart failure with reduced ejection fraction. The drug was approved by the FDA in 2015, and since then, it has been a popular medication among patients. However, the high cost of the medication has been a barrier for many patients who cannot afford it.

According to the sources provided, generic Entresto is not yet available in the market. Novartis, the manufacturer of Entresto, has been fighting to keep its patent on the drug, but the patent is set to expire in 2025. In 2020, Novartis filed a lawsuit against the FDA after the agency rejected its request to block generic versions of Entresto. The company argued that generic versions of the drug could be dangerous and that the FDA had not followed proper procedures in approving them. However, the lawsuit was unsuccessful, and the FDA allowed generic versions of Entresto to be produced.

Despite the FDA's approval, generic versions of Entresto have not yet been released. According to NiceRx, a company that helps patients access affordable medications, the release of generic Entresto may be delayed due to the ongoing legal battle between Novartis and the FDA. However, NiceRx also notes that patients can access alternative medications that are similar to Entresto and may be more affordable.

In conclusion, generic Entresto is not yet available in the market, but it is expected to be released soon. The release of generic versions of the drug may be delayed due to the ongoing legal battle between Novartis and the FDA. However, patients can access alternative medications that are similar to Entresto and may be more affordable.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/ENTRESTO
[2] https://www.fiercepharma.com/pharma/novartis-takes-entresto-generic-fight-fda-again-after-similar-appeal-flopped-april
[3] https://www.nicerx.com/blog/entresto-generic-sacubitril-valsartan/